R&D Systems™ Recombinant Cynomolgus PD-L2/B7-DC Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Manufacturer: R&D Systems™ 9178PL01M
DescriptionMeasured by its binding ability in a functional ELISA. When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD ) is immobilized at 1 μg/mL, 100 μL/well, the concentration of Recombinant Cynomolgus Monkey PD-L2/B7-DC Fc Chimera that produces 50% of the optimal binding response is approximately 0.1-0.6 μg/mL.
|Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.|
|M.W. (Observed): 62-77 kDa, reducing conditions; M.W. (theoretical): 49 kDa|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.|
|B7-DC, bA574F11.2, Btdc, Butyrophilin B7-DC, Butyrophilin-like Protein, CD273, CD273 antigen, CD273PD-1 ligand 2,mgC142240, PD-1-ligand 2, PDCD1L2MGC142238, PDCD1LG2, PDL2, PDL2B7DC, PD-L2PDCD1 ligand 2, programmed cell death 1 ligand 2, Programmed death ligand 2|
|Reconstitute at 100 µg/mL in PBS.|
|>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.|
|Human embryonic kidney cell, HEK293-derived cynomolgus monkey PD-L2/B7-DC protein Cynomolgus Monkey PD-L2/B7-DC (Leu20-Pro219) (N-terminus) Accession # XP_005581839 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)|
|<0.10 EU / 1 µg of the protein by the LAL method.|